Chiesi Farmaceutici SpA has synthesized heterocyclic derivatives acting as Janus kinase (JAK) inhibitors reported to be useful for the treatment of acute lung injury, asthma, chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis.
Guangzhou Fermion Technology Co. Ltd. has received IND approval by China’s National Medical Products Administration (NMPA) for its TYK2 JH2 inhibitor, FZ-007-119.
Morphosys AG’s rare blood cancer treatment hit its phase III primary endpoint but missed statistical significance on a secondary endpoint, sinking the stock for the day. Top-line data from the study treating JAK inhibitor-naïve patients who have the rare blood cancer myelofibrosis showed the combination of pelabresib, a BET inhibitor, and the JAK inhibitor ruxolitinib produced a statistically significant improvement in spleen volume reduction, which was the primary endpoint.
Five years after Gilead Sciences Inc. gave up on momelotinib in the wake of two phase III failures in myelofibrosis, the JAK1/2 and ACVR1 inhibitor has found its way to the market in the hands of GSK plc. Branded Ojjaara, the drug gained U.S. FDA approval for use in intermediate- or high-risk myelofibrosis patients with anemia regardless of prior administration with JAK inhibitors such as Jakafi (ruxolitinib, Incyte Corp.).
Cgenetech (Suzhou, China) Co. Ltd. has divulged cyclopropanamide-containing compounds acting as Janus kinase (JAK) inhibitors, particularly JAK2 and/or JAK1 and/or JAK3, reported to be useful for the treatment of rheumatoid arthritis, ulcerative colitis, atopic dermatitis, systemic lupus erythematosus, essential thrombocythemia, polycythemia vera and myelofibrosis.
By the end of this year, it will become apparent whether Morphosys AG has executed one of the biotechnology industry’s boldest pivots in recent years or has instead blown $1.7 billion of investor cash on a dud. The day of reckoning is coming a little sooner than expected for the Planegg, Germany-based firm, as it has completed recruitment in a phase III trial of pelabresib in first-line myelofibrosis ahead of schedule. Top-line data from the study are now expected before year-end, instead of early 2024.
Nanjing Kangyi Biomedical Center LP has disclosed compounds with dipyrrolopyridine structure acting as Janus kinase (JAK) inhibitors reported to be useful for the treatment of cancer, asthma, atopic dermatitis, psoriasis, rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus and inflammatory bowel disease, among others.
Keythera (Suzhou) Pharmaceuticals Co. Ltd. has divulged new tyrosine-protein kinase JAK3 inhibitors reported to be useful for the treatment of alopecia areata, rheumatoid arthritis, lupus erythematosus, inflammation, allergy, cancer, metabolic diseases and transplant rejection, among other disorders.